MASSACHUSETTS EYE AND EAR INFIRMARY — History
CCN 220075 | 3-year financial timeline | COVID resilience: 83/100
🛡️ Public data only — no PHI permitted on this instance.
$264M
Latest Revenue (FY2022)
+17.6%
Revenue CAGR (3yr)
-36.1%
Financial Timeline
| Metric | FY2020 | FY2021 | FY2022 | YoY (Latest) | CAGR |
|---|---|---|---|---|---|
| Net Patient Revenue | $191M | $245M | $264M | +7.9% | +17.6% |
| Operating Expenses | $323M | $349M | $359M | +3.1% | +5.5% |
| Operating Margin | -69.3% | -42.5% | -36.1% | +15.0% | +0.0% |
| Net Income | $-132M | $-104M | $-95M | +8.2% | +0.0% |
| Licensed Beds | 41 | 41 | 41 | +0.0% | +0.0% |
| Total Patient Days | 4,192 | 4,234 | 4,610 | +8.9% | +4.9% |
| Medicare Day % | 45% | 35% | 33% | -4.1% | -14.1% |
| Medicaid Day % | 5% | 8% | 6% | -22.0% | +5.4% |
COVID Impact & Recovery
Resilience Score: 83/100 — Resilient — strong COVID recovery
Revenue recovery from FY2020 to FY2022: +38.3% ($191M → $264M)
FY2020 captured the initial COVID shock. Strong recovery indicates operational resilience and payer diversification.
Trend Summary
Revenue▲ Growing
Operating Margin▲ Growing
Beds▶ Stable
Medicare Mix▲ Growing
vs State Average ()
Revenue Growth
+17.6%
This Hospital
+7.6%
State Avg
Latest Margin
-36.1%
This Hospital
-4.6%
State Avg
Projections (FY2023-2025)
Extrapolated from 3-year trend using linear projection. Does not account for regulatory or market changes.
| Year | Revenue (proj) | Margin (proj) |
|---|---|---|
| FY2023 (proj) | $300M | -19.6% |
| FY2024 (proj) | $337M | -3.0% |
| FY2025 (proj) | $373M | 13.6% |